Semaglutide authorised as Ozempic is not currently recognised by regulators as causing specific vulvovaginal adverse reactions such as vaginal dryness, vulvovaginal candidiasis, altered discharge, dyspareunia, vaginal atrophy, or vaginal mucosal injury
The molecule tends to aggregate and precipitate at its isoelectric point, forming particles that represent irreversible potency loss
The answer depends on the study, dose, population, treatment length, and whether the medication is approved or investigational
Journal of Allergy and Clinical Immunology Practice, 11(3), 789-798
In a major trial, participants on Mounjaro had greater A1C reductions and more people reached target A1C levels compared with those on semaglutide